Introduction
Evaluation of toxic side effects in rodents is a mandatory step in drug development prior to human trials. Current preclinical standard toxicological analyses include behavioral observations together with histopathological, biochemi c a l , a n d h e m a t o l o g i c a l a n a l y s e s . H o w e v e r , histopathological investigations such as hematoxylin and eosin stainings suffer from inter-and intra-observer Anne Rix, Natascha Ingrid Drude, and Anna Mrugalla have co-first authorship Electronic supplementary material The online version of this article (https:// doi.org/10.1007/s11307-019-01417-3) contains supplementary material, which is available to authorized users. variability, provide only limited spatial information, and may not be representative of the entire organ. Furthermore, longitudinal screening is impossible, resulting in the need to euthanize high numbers of animals [1] . Blood parameters can be obtained longitudinally and are the most applied and cost-efficient measures to evaluate health states in humans and animals. However, it is not always possible to unequivocally assign the measures to a specific organ. Furthermore, the distribution of the markers in the blood occurs with a delay after organ damage and changes may not be detected early due to their strong dilution in the blood. Finally, the amount of blood that can be collected from mice is limited, which is particularly critical in longitudinal investigations.
Today, animal experiments are strictly regulated and the 3R principles (replacement, reduction, and refinement) provide an ethical framework for animal research. In addition to restricting animal experiments to the necessary minimum, the 3R principles aim to improve the quality of animals' life and the scientific output of the experiments [2] . In this view, using non-invasive imaging techniques, like positron emission tomography (PET), for toxicity evaluation, can reduce the required number of animals by enabling longitudinal investigations. Furthermore, the scientific output is improved by reducing sources of errors.
Severe organ toxicity is usually accompanied by an increased rate of cell death [3] . Depending on the underlying mechanism, cell death can be roughly divided into apoptosis and necrosis. During both mechanisms, the phospholipids on the inner leaflet of the cell membrane become accessible to tracers, either as a result of the decreasing cell membrane asymmetry associated with apoptosis or due to the loss of cell membrane integrity during necrosis [4] . (Pre)clinical studies focusing on in vivo cell death imaging are mostly based on molecular imaging of dying cells using labeled annexin V. Annexin V binds to phosphatidylserine, a normally inward facing phospholipid of the cell's lipid bilayer [5] . However, annexin V tracers have some disadvantages, including a slow clearance and a limited tissue penetration, generating a considerably high unspecific background due to their high molecular weight (≥ 36 kDa) [6] . Duramycin is a low molecular weight alternative (2 kDa) that binds to phosphatidylethanolamine (PE), the second most abundant phospholipid on the inner leaflet of viable cells [7] . In previous studies, derivatives of duramycin have been used successfully in the detection of therapyinduced tumor cell death, in the assessment of pulmonary injury and cardiac or cerebral ischemia-reperfusion in different animal models using single-photon emission computed tomography (SPECT) [8] . Recently, Johnson et al. provided a first proof-of-concept for the suitability of Tc-99m labeled duramycin to systemically characterize chemotherapy-induced cell death in rats [9] .
In the present study, we evaluated [ 68 Ga]NODAGAduramycin as a Ga-68-based duramycin tracer for noninvasive detection of chemotherapy-induced organ toxicity in mice using PET combined with X-ray computed tomography (CT). For this purpose, mice received three chemotherapeutics with different mechanisms of action and toxicity profiles: doxorubicin, busulfan, and cisplatin. Doxorubicin (anthracycline) is routinely used to treat different types of cancer, including breast, lung, and thyroid cancers. Doxorubicin is especially known to cause cardiotoxic side effects, but macrophage depletion has also been reported [10, 11] . Busulfan (alkylating agent) is used for treatment of chronic myelocytic leukemia and for myeloablative conditioning prior to hematopoietic stem cell transplantations. In addition to having a myelosuppressive effect, busulfan is associated with pneumo-and cardiotoxicity [12, 13] . Cisplatin (platinum coordination compound) is widely used in the treatment of various types of cancer, including cancers of soft tissue, lungs, and blood vessels. Cisplatin is known for its nephro-and neurotoxicity, but cardio-, hepato-, spleno-, and pulmotoxic effects have also been detected [14, 15] . Here, we show that [ 68 Ga]NODAGA-duramycin PET/CT reliably depicts organ toxicity of these chemotherapeutics in agreement with immunohistochemical analysis of caspase-3 activation and blood/serum parameters.
Materials and Methods

Radiolabeling of NODAGA-Duramycin
For radiolabeling of NODAGA-duramycin (Molecular Targeting Technologies, Inc.), no-carrier-added [ 68 Ga]Cl 3 (in 0.05 M HCl) was eluted from an in-clinic Ge-68/Ga-68 generator (ITM Isotopen Technologien München). 3.92 nmol NODAGA-duramycin was dissolved in ultrapure water (Merck) and 3 M NH 4 CH 3 O 2 (aq) (in ultrapure H 2 O) was added to adjust the pH to 3-4 for radiolabeling with Ga-68 (40-100 MBq) at room temperature. The radiochemical yield (rcy) was determined by Radio-TLC with instant thin layer chromatography (iTLC)-silica strips and citrate buffer as mobile phase and was reproducibly 9 95 %. Radiochemical purity was estimated via high-performance liquid chromatography (HPLC) on a C-18 column (phenomenex) with a mobile phase linear gradient from 90 to 10 % 0.1 % TFA (in HPLC-H 2 O) with 10-90 % acetonitrile over 15 min, with a flow rate of 1 ml/min at room temperature (rcp 9 95 %) (Suppl Fig. 1 , see Electronic Supplementary Material (ESM)).
In vitro Competitive Binding Analysis
Binding specificity of [ 68 Ga ]NODAGA-duramycin was tested in vitro in triplicates using human glioblastoma cells (U-87), neural stem cells (NSC), prostate cancer cells (PC-3 wt), and benign prostatic hyperplasia cells (BPH-1). To induce phosphatidylethanolamine exposure to the outer cell membrane mediated by oxidative stress, apoptosis, and necrosis, 25-30 % ethanol were added to cells with and without competitive blocking. Cells were incubated for 1 h. Binding of the tracer was compared between an untreated control group, the ethanol-treated control group, and an ethanol-treated competition group. After ethanol incubation, all cells were incubated with 0.1 MBq [ 68 Ga]NODAGAduramycin for 90 min. The competition group was simultaneously incubated with [ 68 Ga]NODAGA-duramycin and a 100-fold excess of unlabeled duramycin (40 μg/well; 90 min). After extraction of the medium, washing with PBS, and separation of dead and living cells via centrifugation, fractions of interest were measured for radioactivity using the automatic gamma counter WIZARD 2 (PerkinElmer). The decay corrected cell accumulated activity (dead + living) was calculated relative to the implemented activity and normalized to the overall cell number (dead and alive) as estimated with a Neubauer chamber.
Animal Model
All animal experiments were performed according to German legal requirements and animal protection laws, and were approved by the Authority for Environment Conservation and Consumer Protection of the State of North RhineWestphalia (LANUV).
Mice were housed in groups of three to five per cage in individually ventilated cabinets under specific pathogen-free conditions with a 12 h light and dark cycle in a temperature and humidity-controlled environment according to the guidelines of the "Federation for Laboratory Animal Science Associations" (www.felasa.eu). Water and standard pellets for laboratory mice (Sniff GmbH) were offered ad libitum. Female BALB/cAnNRj mice (age 10-12 weeks; Janvier Labs) were assigned randomly to four groups including untreated controls. Doxorubicin (LC Laboratories) was injected intraperitoneally (i.p.) at days 0, 7, and 14. Toxicity analyses were performed at days 8 and 15. Busulfan (Fresenius Kabi) was injected i.p. at days 0, 2, and 4. Toxicity analyses were performed at days 3 and 5. Cisplatin (Teva) was injected i.p. once. Toxicity analyses were performed 1, 2, and 3 days after injection of cisplatin. The dosages chosen for doxorubicin, busulfan, and cisplatin administration have been shown to cause toxic effects in mice in previous studies [16] [17] [18] . The toxicity analyses included [ 68 Ga]NODAGA-duramycin PET/CT, immunohistochemistry, and blood/serum parameter analysis (animal numbers are listed in Suppl. Table 1 , see ESM).
PET/CT
CT scans were performed using a 360°fly-mode CT acquisition (512 views, 3-5 min) using the Triumph II small animal PET/SPECT/CT (Trifoil Imaging). In vivo PET/CT measurements for toxicity analyses were performed for 20 min at 2 h after i.v. injection of 5-10 MBq 68 Ga]NODAGA-duramycin. All data were reconstructed using a three-dimensional ordered-subset expectation maximization (3D-OSEM) iterative algorithm and corrected for attenuation, scatter, dead time, and decay. For calculation of organ accumulated radioactivity, volumes of interest (VOI) of 0.27 mm 3 were drawn using Imalytics Preclinical software [19] and their mean intensity values calculated. Additionally, a VOI was placed over the whole mouse to determine the total tracer amount. Signal intensities were converted into kBq/ml using a device-specific calibration factor. To correct for errors caused during manual injection, the amount of [ 68 Ga]NODAGA-duramycin in different organs was calculated as percentage of total dose in the whole animal (TD) at the first measurement. For biodistribution analysis, values were normalized to the decay corrected TD.
Representative PET/CT images of transversal sections for visualizing the lung and heart and maximum intensity projections of whole body tracer accumulation in the figures have been created using PMOD.
Biodistribution Analysis
[ 68 Ga]NODAGA-duramycin biodistribution was investigated in cisplatin-treated and -untreated mice (n = 3 per group). Image analysis was performed at 11, 40, 70, 100, 130, 160, and 190 min post-injection and time activity curves (TACs) plotted for organs of interest. The blood filled ventricles of the heart were depicted for blood concentration, and blood half-lives were calculated using a two-phase model for non-linear fitting of the TACs (GraphPad Software).
Blood/Serum Analysis
Blood and serum were collected before euthanasia and analyzed to determine platelet count (PLT), aspartate transaminase (AST), alanine transaminase (ALT), urea, creatinine, and creatine kinase (CK) values.
Indirect Immunohistochemistry
Five randomly selected vision fields per organ were analyzed (for animal numbers see Suppl. Table 1 in ESM). Ex vivo staining of cryosections with 4′,6-diamidino-2-phenylindole (DAPI, Merck) and active caspase-3, which, as duramycin, is an early marker of cell damage [20] , was performed as described previously using rabbit-anti-active caspase-3 IgG (6.45 μg/ml) (Abcam), followed by donkey F(ab′)2 anti-rabbit IgG (H + L)-Cy3 (3 μg/ml) (Dianova) [21] . Area percentages of active caspase-3 and DAPI per fluorescence micrograph were determined using the software Fiji [22] .
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software). Significant differences between groups were assessed using one-way ANOVA followed by Dunnett's multiple comparisons test. Values of p G 0.05 were considered statistically significant. All data are presented as mean ± SD.
Results
Competitive Binding Analysis
Binding specificity of [ 68 Ga]NODAGA-duramycin was evaluated in vitro by competitive binding analysis using human glioblastoma cells (U-87), neural stem cells (NSC), prostate cancer cell line (PC-3 wt), and benign prostatic hyperplasia cells (BPH-1). In all cell lines, quantification of the decay corrected relative cell accumulated activity (rCAA), normalized to the overall cell number, and relative to the implemented activity ( Fig. 1) showed a significantly increased [ 
In vivo Biodistribution
TACs of [ 68 Ga]NODAGA-duramycin ( Fig. 2 ) revealed that [ 68 Ga ]NODAGA-duramycin distributed rapidly throughout the body with highest initial tracer concentrations in the blood and liver. Blood tracer concentration decreased rapidly, and within 120 min, most of the unbound tracer was cleared from circulation. The blood half-life was 10.10 ± 9.25 min for untreated and 17.27 ± 4.12 min for cisplatintreated animals. In cisplatin-treated mice, mean radioactivity in the livers and spleens was consistently higher than in untreated animals and did not show a continuous decline with decreasing blood concentrations. In the kidneys, an enhanced tracer accumulation became visible in cisplatintreated animals after 70 min. Slightly higher values were also found in the hearts of cisplatin-treated animals; however, curves rapidly declined indicating a strong contribution of the blood to the signal at early time points. In all organs, either a plateau level or a decline close to baseline was reached after 130 min. Therefore, this time point was used for toxicity analyses. Radioactivity in the bladder increased until 70-90 min post-injection (p.i.) indicating renal excretion.
Doxorubicin-Induced Organ Toxicity
Compared to untreated mice, doxorubicin administration lead to higher radiotracer concentrations in the liver (Fig. 3a) , which was in line with caspase-3 activation measured by immunohistochemistry (Fig. 3b) . In the kidneys, radiotracer concentrations of doxorubicin-treated mice were higher at day 15 
In the spleen and bone marrow, radiotracer accumulation and blood parameters (Suppl. Table 3 , see ESM) indicated a toxic effect of doxorubicin at day 15. However, spleen toxicity was not reflected in caspase-3 activation.
In the heart and lungs, all analyses indicated organ damages. Heart radiotracer accumulation in doxorubicintreated mice was significantly increased at day 15 (control 1.2 ± 0.2 % TD/ml; d15 2.4 ± 0.6 % TD/ml, p G 0.001) accompanied by a significant increase in caspase-3 activation (control 0.6 ± 0.3 % area; d15 2.2 ± 0.7 % area, p G 0.001) and in CK levels (control 112.4 ± 54.75 U/l; d15 195.3 ± 34.86 U/l, p G 0.05). In the lungs, radioactivity was increased significantly at day 15 (control 1.1 ± 0.2 % TD/ml; d15 2.6 ± 0.6 % TD/ml, p G 0.001), which corresponded to significantly higher caspase-3 activation at days 8 and 15 (control 0.2 ± 0.1 % area; d8 0.6 ± 0.2 % area, p G 0.005; d15 0.7 ± 0.1 % area, p G 0.001). An overview of the detected toxicities and the respective timepoints is displayed in Suppl. Table 4 
in ESM.
Busulfan-Induced Organ Toxicity Busulfan-induced hepatotoxicity was successfully detected by PET/CT (Fig. 4a) (control 41.0 ± 5.3 % TD/ml; d5 53.1 ± 11.8 % TD/ml; p G 0.005) and correlated with immunohistochemistry (Fig.  4b , Suppl. Fig. 2 (see ESM) ) (control 2.1 ± 0.5 % area; d5 3.0 ± 0.1 % area, p G 0.005) but not by serum parameters (Suppl. Table 2 , see ESM). Nephrotoxicity analyses were consistently negative showing no significant changes in any of the applied screenings. Accumulation of [ 68 Ga]NODAGA-duramycin in the bone marrow was significantly higher on days 3 and 5.
Significantly increased radioactivity in the spleen and heart indicated spleno-(control 5.3 ± 0.5 % TD/ml; d5 6.8 ± 2.1 % TD/ml; p G 0.05) and cardiotoxic (control 1.2 ± 0.2 % TD/ml; d3 2.0 ± 0.6 % TD/ml; d5 2.0 ± 0.5 % TD/ml; p G 0.005) effects. Caspase-3 activation showed a similar, however, non-significant trend with a higher variance in the control group.
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In the lungs, toxicity analyses were consistent, but significant differences could be detected earlier by PET/ CT. In detail, significantly increased radiotracer concentrations were observed at days 3 and 5 (control 1.1 ± 0.2 % TD/ ml; d3 2.1 ± 0.5 % TD/ml; p G 0.001; 1.6 ± 0.6 % TD/ml; p G 0.05), whereas caspase-3 activation was only increased at day 5 (control 0.2 ± 0.1 % area; d5 0.4 ± 0.1 % area, p G 0.005). An overview of the detected toxicities and the respective timepoints is displayed in Suppl. Table 4 (see  ESM) .
Cisplatin-Induced Organ Toxicity
Cisplatin-induced hepatotoxicity was detected consistently by PET/CT, immunohistochemistry, and serum parameters. 68 Ga]NODAGA-duramycin in malignant and benign cell lines in a cell death and stress assay using ethanol and a 100-fold excess of unlabeled duramycin (competition). Tracer uptake was significantly reduced in the competition groups. rCAA relative cell accumulated activity. **p G 0.005; ***p G 0.001.
Fig. 2 [
68 Ga]NODAGA-duramycin biodistribution displayed as TACs (10-180 min p.i. in cisplatin-treated and untreated mice for the a liver, b kidneys, c spleen, d heart, e blood, and f bladder. Results indicated a retention in the liver and kidneys, and an accumulation in the bladder. Blood concentrations decreased rapidly. Higher tracer uptake in the liver, kidneys, and spleen after cisplatin treatment highlighted its specificity for damaged organs. TD total dose.
Compared to untreated mice, a significantly higher liver accumulation was detected at days 2 and 3 after cisplatin administration (Fig. 5a ) (control 41.0 ± 5.3 % TD/ml; d2 54.7 ± 7.9 % TD/ml, p G 0.005; d3 67.4 ± 5.8 % TD/ml, p G 0.001) accompanied by a significantly increased caspase-3 activation at day 3 ( Fig. 5b) (control 2.0 ± 0.5 % area; d3 4.3 ± 0.7 % area, p G 0.001). Serum parameter analysis (Suppl . Tables 2 and 3 , see ESM) revealed significantly higher AST levels at day 2 (control 112.1 ± 31.75 U/l; d2 200 ± 89.62 U/l, p G 0.05).
In the kidneys, enhanced tracer uptake was found at day 2. However, differences were not high enough to reach statistical significance. In contrast, differences in caspase-3 activation and serum parameters were more pronounced, indicating acute kidney damage at day 2 [caspase-3 activation: (control 0.4 ± 0.2 % area; d2 1.0 ± 0.1 % area, p G 0.005); urea: (control 8.39 ± 1.23 mmol/l; d2 15.09 ± 7.47 mmol/l, p G 0.05); creatinine: (control 13 ± 1.32 μmol/l; d2 27.67 ± 12.67 μmol/l, p G 0.005)]. Nevertheless, PET and immunohistochemistry data showed a good correlation of R 2 = 0.5429 (Suppl. Fig. 2, see ESM) .
In the spleen and bone marrow, a significant increase in radiotracer accumulation was detected at day 3 compared to control animals (p G 0.001). Tracer uptake in spleen correlated with a significantly increased caspase-3 activation (control 1.0 ± 0.2 % area; d3 10.5 ± 4.8 % area, p G 0.001) and PLT (control 894.5 ± 151.8 10 3 /μl; d3 1147 ± 95.19 10 3 / μl, p G 0.005).
In the heart, radiotracer accumulation was significantly higher at all points in time (control 1.2 ± 0.2 % TD/ml; d1 2.1 ± 0.5 % TD/ml, p G 0.05; d2 2.3 ± 0.5 % TD/ml, p G 0.005; d3 3.0 ± 0.8 % TD/ml, p G 0.001), although no significant changes in caspase-3 activation were detected. However, significantly increased CK values at day 3 confirmed the PET/CT results (control 112.4 ± 54.75 U/l; d3 586.3 ± 396.8 U/l, p G 0.05).
In the lungs, PET/CT and immunohistochemistry were consistent, but PET/CT detected the pneumotoxic effect earlier. A significantly enhanced radiotracer accumulation indicated organ damage at days 1 and 3 after cisplatin administration (control 1.1 ± 0.2 % TD/ml; d1 2.4 ± 1.3 % Fig. 3 Organ toxicity analyses in doxorubicin-treated and untreated mice. a PET/CT showed a significantly increased accumulation in the spleen, heart, lungs, and bone marrow following doxorubicin administration. b Caspase-3 activation revealed a significant increase in apoptosis in the liver, kidneys, heart, and lungs. c Left: transversal section of lung and heart. Right: PET maximum intensity projection (MIP) of tracer accumulation on a CT image. d Representative micrographs of the liver, kidneys, spleen, heart, and lungs show an increase of active caspase-3 on day 15 of doxorubicin treatment compared to control mice (scale bar 50 μm). act casp-3 active caspase-3, b bladder, d day, h heart, k kidneys, li liver, lu lungs, s spleen, TD total dose. *p G 0.05; **p G 0.005; ***p G 0.001. TD/ml, d3 p G 0.05; 4.0 ± 1.2 % TD/ml, p G 0.001), while a significant increase in caspase-3 activation was only detected at day 3 (control 0.2 ± 0.1 % area; d3 0.5 ± 0.1 % area, p G 0.005). An overview of the detected toxicities and the respective timepoints is displayed in Suppl. Table 4 (see  ESM) .
Discussion
The detection of drug-induced organ toxicity via noninvasive imaging could have a valuable impact on preclinical toxicity studies by improving the quality of results and reducing the number of animals needed. In this regard, cell death can be considered a suitable imaging biomarker of tissue toxicity. Recently, Johnson et al. [9] provided a proof of concept that Tc-99m labeled duramycin is a suitable tracer to detect chemotherapy-induced cell death by SPECT. In this study, whole body toxic profiles of cyclophosphamide, methotrexate, and cisplatin were characterized on a single time point in rats. Furthermore, in a first pilot study, the progression of signal changes in rats after treatment with cyclophosphamide was detected. Based on these results, the present study aims on the longitudinal evaluation of chemotherapy-induced tissue damage and the detection of systemic toxicity at an early stage using a duramycinderivative suitable for PET imaging. Compared to SPECT, PET provides a higher sensitivity [23] . In this context, Yao et al. synthesized N-(2-18 F-fluoropropionyl)duramycin and focused on the detection of cisplatin or cyclophosphamideinduced cell death, however, solely in tumor tissue [24] . Alternatively, duramycin can be labeled using Ga-68 [25] , a generator-eluted radionuclide that combines economical and practical advantages, including no need for a cyclotron on site (as for F-18) and a less time-consuming synthesis due to the applicability of coordination chemistry [26] . Disadvantages arising from the higher maximum positron energy of Ga-68 (1.92 MeV compared to F-18 (0.63 MeV)), which can potentially result in a lower spatial resolution (1.4 mm (F-18) versus 2.4 mm (Ga-68) in a small animal PET scanner) [27] as well as the higher dose rate, need to be considered. On the other hand, the shorter half-life of Ga-68 as compared to F-18 can be beneficial for longitudinal Fig. 4 Organ toxicity analyses in busulfan-treated and untreated control mice. a PET/CT showed a significantly increased % TD/ml in the liver, spleen, heart, lungs, and bone marrow following busulfan administration. b Caspase-3 activation revealed a significant increase in apoptosis in the liver and lungs. c Left: transversal section of lung and heart. Right: PET MIP of tracer accumulation on a CT image. d Representative micrographs show an increase in active caspase-3 in the liver and lungs on daystudies since it allows imaging at shorter intervals. In addition, different to previous publications reporting on positron labeled duramycin [24, 25] , we conjugated NODAGA (1-(1,3-carboxypropyl)-1,4 ,7-triazacyclononane-4,7-diacetic acid) to enable the complexation of Ga-68. This chelating system allows radiolabeling at room temperature which is preferred especially for temperature sensitive peptides or proteins. Since the chelator and the radionuclide change the pharmacokinetics of duramycin [28] and since we intended to perform our analyses in mice, biodistribution analyses were performed. In this context, it is noteworthy that mice generally show different pharmacokinetics and toxicity profiles than rats [29] . Consequently, we applied different chemotherapy treatment protocols to induce tissue damage in mice. Thus, although both studies confirm the suitability of duramycin as a molecule to detect cell death, the direct comparison of tracers' performances is not possible and open to further investigation.
Specific binding of [ 68 Ga]NODAGA-duramycin to damaged cells was confirmed in vitro. Analogue in vivo competitive binding experiments could not be accomplished since nephrotoxic effects of high duramycin doses [30] in cisplatin pre-damaged kidneys inhibited renal excretion of the radiotracer and strongly altered its pharmacokinetics (data not shown). The in vivo biodistribution analysis revealed a higher blood half-life in cisplatin-treated mice compared to control animals, which might have been caused by a reduced glomerular filtration rate due to the nephrotoxicity of cisplatin. Nevertheless, the unbound radiotracer underwent fast urinary excretion. However, some retention was found in the livers and kidneys. Liver accumulation can be a result of partial biliary excretion, the higher baseline apoptosis rate in this organ, or the unspecific uptake by the mononuclear phagocyte system. Enhanced kidney concentration after 70 min indicated a slight unspecific kidney retention, a common observation for peptide-based tracers [31] . Both the unspecific liver uptake and the renal retention create a baseline signal, which needs to be considered when analyzing toxicological side effects. However, since the concentration of non-specifically retained tracer was stable over time, specific accumulation could still be detected. Confirmation of small differences in tracer accumulation as valid organ toxicity may still require the complementary use of additional measures such as serum parameters [32] . Furthermore, hepatobiliary clearance and, to a lesser extent, kidney retention may be tuned by changing the chelator. However, NODAGA already appears to be one of the chelators with the lowest accumulation in the liver [33] [34] [35] .
D e s p i t e t h e d i s c r e t e u n s p e c i f i c u p t a k e o f [ 68 Ga ]NODAGA-duramycin, we were able to reliably detect doxorubicin-, busulfan-, and cisplatin-induced organ toxicity by PET/CT. As expected, doxorubicin administration had a cardiotoxic effect that resulted in a significantly higher radiotracer accumulation in the heart. Additionally, toxic effects on the spleen and lungs were detected via PET/CT and confirmed by increased PLT and caspase-3 activation, respectively. This effect could be expected since doxorubicin is known to deplete CD169 + macrophages in the spleen and lungs [10] . Considering that splenic macrophages are responsible for the clearance of senescent platelets, an increased PLT is an additional indicator for the splenotoxic effect of doxorubicin [36] .
In contrast, the hepato-and nephrotoxic effects, which were obvious in immunohistochemistry and serum parameter analysis, were less pronounced in [ 68 Ga]NODAGAduramycin PET/CT, which may be due to the enhanced unspecific uptake in these organs. As discussed above, in such cases, the complementary analysis of selected serum parameters may help to confirm the PET/CT results.
Busulfan-related pneumotoxicity was detected earlier by [ 68 Ga ]NODAGA-duramycin PET/CT than by immunohistochemistry, which did not show a pneumotoxic effect before day 5. Additionally, organ radiotracer concentrations indicated a toxic effect on the liver, spleen, and heart. The same trend was found in immunohistochemistry, supporting previous reports in the literature [12, 13] . However, in immunohistochemistry, differences only reached significance for the hepatotoxic effect, also indicating the sensitivity of the [ 68 Ga]NODAGA-duramycin PET/CT approach. The potentially higher sensitivity in the detection of toxic effects by the radiotracer can be explained by the fact that caspase-3 activation is only related to apoptosis, whereas PE becomes accessible during apoptosis, necrosis, and oxidative stress [3] . Moreover, PET detects the toxicity at the whole organ level, whereas histology only focuses on a limited area of the organ. Since at early time points, there are only few apoptotic cells per histological slide, the statistical validity is poor and prone to outliers. Consequently, large numbers of histological samples would need to be investigated to achieve the same sensitivity like [ 68 Ga]NODAGAduramycin PET. When comparing blood analysis with [ 68 Ga ]NODAGA-duramycin PET, it is worth mentioning that an elevation of blood/serum parameters often cannot be detected before substantial tissue damage occurs since molecules are diluted in the whole blood volume, whereas the tracer is concentrated at a specific location in the body.
Cisplatin administration caused hepato-, spleno-, cardio-, and pulmotoxic effects that were successfully detected via PET/CT and confirmed by immunohistochemistry as well as b l o o d / s e r u m p a r a m e t e r a n a l y s i s , a n d a g a i n [ 68 Ga ]NODAGA-duramycin PET/CT depicted significant differences in the heart and lung prior to immunohistochemistry and serum analysis. The [ 68 Ga]NODAGA-duramycin uptake in the kidneys after cisplatin treatment was in agreement with immunohistochemistry, but differences were too small and variations too high to reach statistical significance. Here, we face the same situation as for doxorubicin, where an enhanced unspecific uptake makes the detection of small changes difficult. As statistical significances are depending on many factors such as number of animals per group, number of tests (multiple testing), and heterogeneity within the group, in some unclear cases, it might be favorable to use each animal as its own control to detect alterations [9] .
Conclusion
[ 68 Ga]NODAGA-duramycin PET/CT is a promising approach to assess drug-related side effects and organ toxicity in mice. It may be used additionally to immunohistochemistry and blood sampling, and thereby, contribute to the refinement and reduction of animal experiments in pharmaceutical research. Although the analysis of serum parameters is still necessary to confirm moderate effects, [ 68 Ga]NODAGA-duramycin PET/CT provides a valuable overview of all organs and reinforces the serum parameter analysis that is sometimes ambiguous regarding a specific organ. In addition, fewer serum parameters need to be analyzed, and thus, a smaller blood volume has to be collected. Furthermore, [ 68 Ga]NODAGA-duramycin PET/ CT allows for longitudinal investigations, which improves comparability since each animal can be used as its own control, and reduces bias in preclinical standard toxicological methods such as histopathological investigations. Beyond that, the tracer has a high translational potential for example for the detection of unwanted side effects during chemotherapy. Nephrotoxicity [14] or cardiotoxicity [10] are among the most frequent adverse reactions of several chemotherapeutic agents, and a rapid diagnosis and adaptation of the treatment could reduce long-term complications in patients. 
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